Moderna plans mix of COVID-19 vaccine doses with new Lonza deal
It has agreed a deal with Swiss-based drugmaker Lonza which said a new drug substance production line in Geleen, Netherlands, will have capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose.
Source: indiatimes.com